Journal
NATURE COMMUNICATIONS
Volume 10, Issue -, Pages -Publisher
NATURE PUBLISHING GROUP
DOI: 10.1038/s41467-019-10677-0
Keywords
-
Categories
Funding
- National Institute of Arthritis and Musculoskeletal and Skin Diseases of the National Institutes of Health [R01AR43510, P30 AR069655, AR063650]
- National Institute for Aging [R01AG049994, 1S10RR027340]
- National Institutes of Health
Ask authors/readers for more resources
Inflammaging induces osteoporosis by promoting bone destruction and inhibiting bone formation. TRAF3 limits bone destruction by inhibiting RANKL-induced NF-kappa B signaling in osteoclast precursors. However, the role of TRAF3 in mesenchymal progenitor cells (MPCs) is unknown. Mice with TRAF3 deleted in MPCs develop early onset osteoporosis due to reduced bone formation and enhanced bone destruction. In young mice TRAF3 prevents beta-catenin degradation in MPCs and maintains osteoblast formation. However, TRAF3 protein levels decrease in murine and human bone samples during aging when TGF beta 1 is released from resorbing bone. TGF beta 1 induces degradation of TRAF3 in murine MPCs and inhibits osteoblast formation through GSK-3 beta-mediated degradation of beta-catenin. Thus, TRAF3 positively regulates MPC differentiation into osteoblasts. TRAF3 deletion in MPCs activated NF-kappa B RelA and RelB to promote RANKL expression and enhance bone destruction. We conclude that pharmacologic stabilization of TRAF3 during aging could treat/prevent age-related osteoporosis by inhibiting bone destruction and promoting bone formation.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available